A-plus

Houston STEM high school declared top of the class by U.S. News & World Report

DeBakey High School for Health Professions is at the top of the class. Photo by skynesher/Getty Images

Three Houston high schools deserve a tip of the cap (or mortarboard) after earning marks for excellence. On June 12, U.S. News & World Report released its annual Best U.S. High Schools by metro area, ranking the top public schools in each major city.

DeBakey High School for Health Professions is at the top of the class in the Bayou City. In addition to earning top marks for academics, the school is notably comprised of mostly minority students — 89 percent.

To determine the country's best schools, U.S. News ranked each school using six metrics, applying different weights to each category:

  • College readiness (30 percent)
  • Math and reading proficiency (20 percent)
  • Math and reading performance (20 percent)
  • Underserved service (10 percent)
  • College curriculum breadth (10 percent)
  • Graduation rate (10 percent)

Based on the above, the school has an overall score of 99.9 (or an A-plus in high school lingo), complete with 100 percent graduation and reading and mathematics proficiency rates. Also, 100 percent of students took and passed at least one AP exam.

Located on the prestigious Texas Medical Center Campus, DeBakey offers students unparalleled access to on-site research facilities, as well as future academic opportunities, U.S. News notes.

"Graduates are eligible for the Houston Premedical Academy, an undergraduate program at the University of Houston designed specifically for DeBakey High School students," the report says. "Those selected for the premedical academy receive provisional acceptance to the Baylor College of Medicine."

DeBakey ranks first in Houston and No. 17 nationally. The school is also rated No. 10 in the U.S. among magnet schools and No. 11 among STEM schools.

Carnegie Vanguard High School earned the No. 2 spot in Houston, 24th in the nation, followed by Eastwood Academy at No. 3 locally and 97th nationally.

---

A version of this story, with information on Texas' other metros, originally was published on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted